Since this review focuses on novel and promising targeted therapies potentially available for study in pediatric AML in the near future, an exhaustive review of all the Ras/MAPK and PI3K/Akt/mTOR signaling inhibitors is beyond our scope, and only few examples will be reported. The gene discussed is MTOR; the disease is acute myeloid leukemia.